Luca Issi
Stock Analyst at RBC Capital
(3.72)
# 763
Out of 5,239 analysts
224
Total ratings
50%
Success rate
7.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $80 → $87 | $79.04 | +10.07% | 12 | May 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Sector Perform | $66 | $52.88 | +24.81% | 13 | May 5, 2026 | |
| MRNA Moderna | Maintains: Sector Perform | $35 → $38 | $53.27 | -28.67% | 20 | May 4, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $445 | $292.03 | +52.38% | 30 | May 1, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $95 → $100 | $75.83 | +31.87% | 12 | Apr 30, 2026 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $100 | $65.95 | +51.63% | 1 | Apr 9, 2026 | |
| QURE uniQure | Upgrades: Outperform | $11 → $35 | $29.10 | +20.27% | 8 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Sector Perform | $9 → $15 | $13.99 | +7.22% | 8 | Mar 3, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $250 → $275 | $237.65 | +15.72% | 5 | Mar 3, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $925 → $890 | $812.81 | +9.50% | 4 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $22 → $26 | $31.58 | -17.67% | 8 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $9 → $27 | $6.79 | +297.64% | 6 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $10 | $6.96 | +43.68% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $57 → $28 | $28.42 | -1.48% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $85 → $8 | $11.22 | -28.70% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $42 → $50 | $52.83 | -5.36% | 15 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $19 | $10.24 | +85.55% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $30 | $18.37 | +63.31% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $61 → $72 | $13.14 | +447.95% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.30 | +334.78% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $41.06 | -56.16% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $5.70 | +250.88% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $9.16 | +85.59% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $9.79 | +32.79% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $10.34 | +238.49% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $55.64 | +2.44% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.93 | +36.52% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $26.84 | +186.89% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.03 | +589.66% | 5 | Aug 7, 2024 |
Arrowhead Pharmaceuticals
May 8, 2026
Maintains: Outperform
Price Target: $80 → $87
Current: $79.04
Upside: +10.07%
BioMarin Pharmaceutical
May 5, 2026
Reiterates: Sector Perform
Price Target: $66
Current: $52.88
Upside: +24.81%
Moderna
May 4, 2026
Maintains: Sector Perform
Price Target: $35 → $38
Current: $53.27
Upside: -28.67%
Alnylam Pharmaceuticals
May 1, 2026
Maintains: Outperform
Price Target: $450 → $445
Current: $292.03
Upside: +52.38%
Ionis Pharmaceuticals
Apr 30, 2026
Maintains: Outperform
Price Target: $95 → $100
Current: $75.83
Upside: +31.87%
BridgeBio Pharma
Apr 9, 2026
Initiates: Outperform
Price Target: $100
Current: $65.95
Upside: +51.63%
uniQure
Mar 9, 2026
Upgrades: Outperform
Price Target: $11 → $35
Current: $29.10
Upside: +20.27%
Intellia Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $9 → $15
Current: $13.99
Upside: +7.22%
Ascendis Pharma
Mar 3, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $237.65
Upside: +15.72%
argenx SE
Feb 27, 2026
Maintains: Outperform
Price Target: $925 → $890
Current: $812.81
Upside: +9.50%
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $26
Current: $31.58
Upside: -17.67%
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $6.79
Upside: +297.64%
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $6.96
Upside: +43.68%
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $28.42
Upside: -1.48%
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $11.22
Upside: -28.70%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $52.83
Upside: -5.36%
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $10.24
Upside: +85.55%
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $18.37
Upside: +63.31%
Oct 28, 2025
Downgrades: Sector Perform
Price Target: $61 → $72
Current: $13.14
Upside: +447.95%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $2.30
Upside: +334.78%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $41.06
Upside: -56.16%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $5.70
Upside: +250.88%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $9.16
Upside: +85.59%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $9.79
Upside: +32.79%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $10.34
Upside: +238.49%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $55.64
Upside: +2.44%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.93
Upside: +36.52%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $26.84
Upside: +186.89%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $2.03
Upside: +589.66%